Navigation Links
New Data Showed Minimal Potential for Drug Interaction Between Cholesterol Drug LIVALO® and a Common Antiretroviral Therapy
Date:7/18/2011

ther. 1999; 33:859-63.

(8) Kaul DR, Cinti SK, Carver PL et al. HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications. Pharmacotherapy. 1999; 19:281-98.

About Kowa Company, Ltd. and Kowa Pharmaceuticals America, Inc.

Kowa Company, Ltd. (KCL) is a privately held multinational company headquartered in Nagoya, Japan. Established in 1894, KCL is actively engaged in various manufacturing and commercial activities in the fields of pharmaceutical, life science, information technology, textiles, machinery and various consumer products. KCL's pharmaceutical division is focused on cardiovascular therapeutics, with sales of the company's flagship product LIVALO, totaling $530 million (14.6% market share) in Japan in the 2010 fiscal year, and was launched in the United States in June 2010.

Kowa Pharmaceuticals America, Inc. (KPA) is a pharmaceutical company specializing primarily in the area of cardiometabolic diseases. The company, started in 2001 as ProEthic Pharmaceuticals, Inc., was acquired by KCL in September of 2008. A privately held company, KPA directs its efforts towards the acquisition, licensing and marketing of pharmaceutical products.  

exchange rate used $1=85JPY

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.   P-LLY

This news release contains forward-looking statements. These statements are subject to known and unknown risks and uncertainties that may cause
'/>"/>

SOURCE Kowa Pharmaceuticals America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
2. One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
3. New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
4. CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
5. New Data Showed ACTOS(R) (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes
6. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
7. New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
8. Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
9. Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes
10. Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
11. Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... May 1, 2015  CytRx Corporation (CYTR), a ... today reported financial results for the three months ... of recent accomplishments and upcoming milestones for its ... milestones in the early months of 2015, including ... trial of aldoxorubicin in patients with soft tissue ...
(Date:5/1/2015)... Pharmacyclics, Inc. (the "Company") (NASDAQ: PCYC ) today ... 2015, as well as general business updates. Due to ... be held. Key Highlights , Total ... to $206 million from $119 million for the quarter ... (ibrutinib) net product revenue of $247 million was ...
(Date:5/1/2015)... , May 1, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of innovative therapies for the ... Timothy E. Morris , chief financial officer  will ... the events are as follows: Mizuho Third ... Location:  The Omni Berkshire Place, New York ...
Breaking Medicine Technology:CytRx Reports First Quarter 2015 Financial Results 2CytRx Reports First Quarter 2015 Financial Results 3CytRx Reports First Quarter 2015 Financial Results 4CytRx Reports First Quarter 2015 Financial Results 5CytRx Reports First Quarter 2015 Financial Results 6CytRx Reports First Quarter 2015 Financial Results 7CytRx Reports First Quarter 2015 Financial Results 8CytRx Reports First Quarter 2015 Financial Results 9CytRx Reports First Quarter 2015 Financial Results 10CytRx Reports First Quarter 2015 Financial Results 11Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 2Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 3Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 4Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 5Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 6Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 7Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 8Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 9Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 10Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 11Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 12Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 13Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 14Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 15Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 16Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 17Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 18Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 19Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 20Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 21Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 22Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 23Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 24Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 25Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 26
... Greenway Medical Technologies, Inc. and the Physician ... (INHS) today announced an agreement for INHS to ... practice management solution PrimeSUITE® 2011 to ... coordination and network interoperability. Established more ...
... Cohera Medical, Inc.®, a rapidly growing medical device company, ... for its lead product, TissuGlu® Surgical Adhesive. ... sold in the European Union. TissuGlu ... surgeries, such as abdominoplasties, that helps reduce fluid accumulation ...
Cached Medicine Technology:Greenway Partners With INHS to Advance EHR Adoption 2Greenway Partners With INHS to Advance EHR Adoption 3Cohera Medical Receives CE Mark Approval for TissuGlu® Surgical Adhesive 2Cohera Medical Receives CE Mark Approval for TissuGlu® Surgical Adhesive 3
(Date:5/4/2015)... (PRWEB) May 04, 2015 “St. Louis ... the “Gateway to the West,” so it is the ... Veterans Program”, says Dr. Ben Litalien, Chief Development Officer ... Association’s VetFran program and will provide veterans with a ... Zerorez® is proud to have a number of Military ...
(Date:5/3/2015)... Metamora, Michigan (PRWEB) May 03, 2015 Barbara Crone ... worked to enhance the well being of the men, women and ... a hospital, followed by providing care for families in the home. ... an Adult Nurse Practitioner began wondering if I could complete their ... of my own children with my mentor Nurse Midwife, I knew ...
(Date:5/3/2015)... Bubbly Walrus ” was featured on NewsWatch as part of ... and coolest applications on the market for iOS, Android, and ... conducted the app review and shared with viewers how this ... to play on smartphones are the ones that get users ... a video game that just absorbs attention, why not exercise ...
(Date:5/3/2015)... May 03, 2015 NuevaCare announced today ... two upcoming area seminars. The first event will take ... Regional Stroke Conference to be held at The Magnolia ... Wednesday, May 13 during the Dementia Conference to be ... “These seminars offer an excellent opportunity to learn about ...
(Date:5/2/2015)... 2015 As one of only 30 ... Safety and Health Achievement and Recognition Program (SHARP) certification, ... chosen by the Illinois Department of Labor to host ... maintained SHARP certification by the Occupational Safety and Health ... has continued to meet or exceed all of the ...
Breaking Medicine News(10 mins):Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 2Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 3Health News:Women's Excellence In Midwifery Welcomes Barbara Crone 2Health News:An Application to Have Fun with Mathematics Was Featured on NewsWatch Television 2Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3
... Inc. told the National Heritage Insurance Co., the contractor that ... to cover its test. ,After this the company’s ... to $12.41 on Nasdaq. The company prepares oncotype DX breast ... taking all the responsibility to cover the medical expenses related ...
... virus has been steadily increasing, with more// than 50 ... in other parts of the territory. // Furthermore, reports of ... past three weeks has prompted reasons for concern among the ... occurred has been one that hit Darwin a decade ago ...
... time from six weeks to five days. This is very useful ... can point the radiation source at the tumor killing the cancer ... therapy over the conventional six-week treatment. They are also in the ... ,But the Canadians are working on a new therapy for breast ...
... Scientist working at the DeCode Genetics Inc (Reykjavik company) was ... the diabetic population in US. ,The Icelandic ... is not known, but is thought to regulate the genes ... in the Icelandic population, as they are a close nit ...
... Pathology, University of Michigan Medical School has reported in ... for producing hypersensitive immune response leading to autoimmune disease. ... the bacteria against which the protein produces an immune ... the immune system to produce an immune response against ...
... the fourth largest reservoir of scientific and research talent ... is poised to emerge as the preferred hub for ... knowledge economy are not restricted to information and communication ... biotech, nanotechnology, missile technology and space. ,India's ...
Cached Medicine News:Health News:Western Australia Witnesses Rise In Ross River Virus Infection 2Health News:Gene Linked To Type 2 Diabetes Identified 2Health News:India set to become the global knowledge hub 2Health News:India set to become the global knowledge hub 3Health News:India set to become the global knowledge hub 4
Insert only, Ethicon medium-large clip size...
Ethicon, medium-large clip size, 10mm, rotatable take apart...
... and IMMULITE 1000 assays are ... IMMULITE and IMMULITE 1000, continuous ... offer simplicity in both design ... be found in a wide ...
... Piccolo is the first compact, broad menu ... testing in any treatment setting. Care givers ... panels with less than one minute of ... comparable in quality to larger, expensive laboratory ...
Medicine Products: